| + |
blinatumomab | down-regulates activity 
binding
|
CD33 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259889 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 25883042 |
Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced member of bispecific T-cell engager (BiTE®) molecules. all data strongly suggest CD33 as a suitable target antigen for BiTE® therapy in AML. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
blinatumomab | down-regulates activity
binding
|
CD19 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259888 |
|
|
Homo sapiens |
Acute Lymphoblastic Leukemia Cell |
| pmid |
sentence |
| 25883042 |
Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced member of bispecific T-cell engager (BiTE®) molecules.Blinatumomab recently gained approval in the United States by the U.S. Food and Drug Administration for treatment of Philadelphia chromosome-negative B-precursor relapsed/refractory acute lymphoblastic leukemia. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
blinatumomab
